ClinicalTrials.gg
CompletedNCT07445958Updated Mar 4, 2026

In-Clinic Assessment of Vaginal Mucosal Safety Following Repetitive Use of the Livi Device

An interventional study of Livi Postcoital Tampon Device in Vaginal Discharge and Postcoital Vaginal Changes, sponsored by Atlantic Health System. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Atlantic Health System · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Vaginal Discharge with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaginal Discharge · United States.

Enrollment
7th of 10
60 · median 91
Started
2026
the only one that year
No phase
7 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Atlantic Health System

Among the 10 studies in Vaginal Discharge with a site in United States, this one is the 7th largest by enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 9th registered.

Vaginal Discharge

21 studies on the registry are indexed under Vaginal Discharge; 2 are open to participants now.

Browse Vaginal Discharge studies →

Open to participants now

1 of the 10 studies in Vaginal Discharge with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Vaginal Discharge study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Vaginal Discharge with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the Livi postcoital tampon device is safe for repetitive use in sexually active women aged 18 years and older. The main question it aims to answer is:

Does using the Livi device three times in a row cause any visible vaginal mucosal trauma? How much pain or discomfort do participants experience during insertion and removal?

Researchers will not compare the Livi device to another product because this is a single-arm safety study.

Participants will:

  • Insert and remove the Livi device three times consecutively during one clinic visit
  • Undergo a baseline speculum exam and digital colposcopy exams after each device removal to check vaginal tissue
  • Complete a 24-hour follow-up via e-diary or phone call to report pain, spotting, or other symptoms
  • Report any unsolicited symptoms for 7 days after use
03

Conditions studied

  • Vaginal Discharge
  • Postcoital Vaginal Changes

Browse trials for

Keywords

  • tampon device
  • postcoital
  • vaginal mucosa
  • device safety
  • sexual intercourse
  • pelvic exam
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sexually active women aged ≥18 years
  • Able and willing to comply with all study procedures
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Current pregnancy or within 6 weeks postpartum
  • Symptomatic vaginal infection, lesion, or vulvovaginal discomfort at baseline
  • Known allergy to any component of the study device
  • Pelvic or vaginal surgery within the past 6 weeks
  • Any medical or psychological condition that, in the investigator's opinion, may interfere with participation or safety
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Livi Device Safety Evaluation

    Participants will insert and remove the Livi device three times consecutively during a single clinic visit.

    Device: Livi Postcoital Tampon Device

Interventions

  • DeviceLivi Postcoital Tampon Device

    Single-use polyurethane foam pledget inserted via disposable applicator, designed to absorb semen post-intercourse.

06

What researchers measure

Primary outcomes

  1. Incidence of Grade ≥2 vaginal mucosal trauma

    Incidence of Grade ≥2 vaginal mucosal trauma assessed immediately after device removal via digital colposcopic examination. Mucosal trauma defined as: Grade 2 (Moderate): Abrasion \>5 mm or multiple foci totaling \>10 mm; pinpoint bleeding stopping spontaneously. Grade 3 (Severe): Laceration or bleeding requiring medical intervention.

    Time frame: Immediate post-use (within 5 minutes of device removal)

Secondary outcomes

  1. Pain/discomfort during insertion/removal

    Immediately after device insertion and removal, Numeric Rating Scale (0- no pain to 10- maximum pain) will be self-reported by patient.

    Time frame: During Visit 1, immediately after device insertion/removal, and at 24-hours (+/- 6 hr)

  2. Ease of use

    Likert scale on ease of overall device use - Very Easy, Easy, Neither Easy Nor Difficult, Difficult, Very Difficult

    Time frame: During Visit 1 immediately following third device insertion

  3. Spotting or pain within 24 hours post-use

    self-reported by subject on e-diary or telephone survey

    Time frame: 24-hour (+/- 6hr) follow-up

  4. Allergy and Hypersensitivity Responses

    Mucosal changes consistent with allergy or hypersensitivity (eg edema, urticaria, swelling, itching) will be documented - this will be both reported subjectively by the patient, and objectively reported by the clinician using digital colposcopy examinations.

    Time frame: after each study device removal, and up to 7 days following visit 1

07

Study locations

1 site
  • Garden State Urology
    Mountain Lakes, New Jersey 07046, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Feb 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Mar 3, 2026
StartActual
Jan 28, 2026
Primary completionActual
Feb 9, 2026
CompletionActual
Feb 9, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445958
Lead sponsor
Atlantic Health System
Responsible party
Michael Ingber (Physician, Atlantic Health System) — Principal investigator
First posted
Mar 3, 2026
Start date
Jan 28, 2026
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion